Shots:

• The P-III (VIRGO) trial evaluating the safety & efficacy of Vuity (pilocarpine HCI ophthalmic solution, 1.25%) vs PBO in a ratio (1:1) in 230 patients aged 40 to 55yrs. with presbyopia
• The trial met its primary efficacy 1EPs i.e., patients treated with Vuity showed an improvement in near vision without compromising distance vision @ Day 14, 9 hr. The safety profile was similar to that observed in studies with Vuity (qd) & the results will be presented at upcoming medical congresses
• The company plans for the sBLA submission for BID administration to the US FDA Q2’22. Vuity (qd) is an optimized formulation of pilocarpine & the 1st US FDA-approved eye drop therapy for presbyopia or age-related blurry near vision

Ref: PR Newswire | Image: PR Newswire